Convertible Note effective October 28, 2019

EXHIBIT 10.47

NEITHER THIS NOTE NOR THE SECURITIES INTO WHICH THIS NOTE IS CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER ANY STATE SECURITIES LAW AND NEITHER THIS NOTE NOR ANY INTEREST THEREIN NOR THE SECURITIES INTO WHICH THIS NOTE IS CONVERTIBLE MAY BE OFFERED, SOLD, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT AND SUCH LAWS OR AN EXEMPTION FROM REGISTRATION UNDER SUCH ACT AND SUCH LAWS WHICH, IN THE OPINION OF COUNSEL SATISFACTORY TO THE COMPANY, IS AVAILABLE.

CELL SOURCE, INC.

8.0% Convertible Note

This Convertible Note (the “Note”) is issued by Cell Source, Inc., a Nevada corporation (the “Company”), effective as of the 28th day of October 2019 (the “Issuance Date”), to Darlene D. Soave (the “Lender”) pursuant to the exemptions from registration under the Securities Act of 1933, as amended.

ARTICLE I

PAYMENTS OF PRINCIPAL AND INTEREST; EVENTS F DEFAULT

Section 1.1 For value received, the Company promises to pay to Lender, or her registered assigns, the lesser of (a) One Million Five Hundred Thousand Dollars ($1,500,000) or (b) the actual amount advanced to the Company by the Lender (the “Principal Amount”) pursuant to the terms, conditions and provisions of this Note. The Company shall pay interest to the Lender on the outstanding Principal Amount of this Note in accordance with Section 1.2 below and such interest shall accrue on each advance of funds from the Lender (each an “Advance”) from the date of such Advance. The Company hereby acknowledges that as of the Issuance Date, the Lender has advanced Five Hundred Thousand Dollars ($500,000) to the Company and it is anticipated that Lender will make additional Advances in the aggregate amount of One Million Dollars ($1,000,000) during the four (4) month period following the Issuance Date. The Principal Amount and all accrued and unpaid interest thereon shall be due on October 31, 2020 (the Maturity Date”).

Section 1.2 Interest shall accrue daily from the date of each Advance at a rate equal to eight percent (8%) per annum and shall be payable on the Maturity Date.

Section 1.3 All payments of principal and interest shall be made to the Lender at the address set forth in Section 3.1or such other address as the Lender shall notify the Company in writing ten (10) days prior to the due date of any payment or upon any prepayment of this Note as provided herein.

Section 1.4 The occurrence of any of the following events of default ( each an “Event of Default”) shall, at the option of the Lender, make all sums of principal and interest then remaining unpaid hereon and all other amounts payable hereunder immediately due and payable, upon demand, without presentment:

(a) the Company fails to pay the Principal Amount and all accrued and unpaid interest on or before the Maturity Date.

(b) the Company breaches any other provision of this Note and such breach is not cured within twenty (20) days after written notice thereof to the Company.

(c) bankruptcy or insolvency proceedings or other proceedings or relief under any bankruptcy law or any other law, or the issuance of any notice in relation to such event, for the relief of debtors shall be instituted by the Company.

ARTICLE II

CONVERSION RIGHTS; CONVERSION PRICE

Section 2.1 Conversion. The Lender shall have the right, at any time after the Company sells shares of its Series B Convertible Preferred Stock (the “Series B Stock”) to convert at any time, all or a portion of the outstanding Principal Amount and accrued and unpaid interest into fully paid and non-assessable shares of the Company’s Series B Convertible Preferred Stock (the “Series B Stock”) at a conversion price (the “Conversion Price”) equal to the price paid by the investors in the Company’s offering of Series B Stock (expected to be $7.50 per share). Promptly after the surrender of this Note, accompanied by a Notice of Conversion of Convertible Note in the form attached hereto as Exhibit 1, properly completed and duly executed by the Lender (a “Conversion Notice”), the Company shall issue and deliver to or upon the order of the Lender that number of shares of Series B Stock for that portion of this Note to be converted as shall be determined in accordance herewith.

No fraction of a share or scrip representing a fraction of a share will be issued on conversion, but the number of shares issuable shall be rounded to the nearest whole share. The date on which Notice of Conversion is given (the “Conversion Date”) shall be deemed to be the date on which the Lender delivers the Notice of Conversion duly executed to the Company. Electronic delivery of the Notice of Conversion shall be accepted by the Company at the e-mail address: “ ***@***”. Certificates representing Series B Stock issuable upon conversion will be delivered to the Lender within five (5) Days of the date the Notice of Conversion is delivered to the Company. Delivery of shares upon conversion shall be made to the address specified by the Lender in the Notice of Conversion.

Section 2.2 Conversion. The number of shares of Series B Stock to be issued upon each conversion of this Note shall be determined by dividing (i) the amount of the Principal Amount and accrued and unpaid interest to be converted by (ii) the Conversion Price.

Section 2.3 Option. In the event that the Company is awarded a a grant by the Cancer Prevention and Research Institute of Texas ( a “CPRIT Grant”) and the Lender has converted all or a portion of this Note into Series B Stock, then the Lender will have the option (the “Option”), but not the obligation to purchase, at an exercise price of $1.25 per share, a number of shares of the Company’s Common Stock that shall be determined by multiplying 7,400,000 by a fraction, the numerator of which shall be the number of shares of Series B Stock owned by the Lender and the denominator of which shall be 666,666. The Company shall provide written notice to the Lender of each funding of the CPRIT Grant and the Option must be exercised within thirty (30) says after the receipt of such notice (the “Funding Notice”) by the Lender sending written notice to the Company of the exercise of the Option and the number of shares being purchased. The number of shares that may be purchased following the receipt of the Funding Notice shall be proportionate to the ratio that the amount being funded bears to the total amount of the CPRIT Grant. By way of example, if 1/3 of the total CPRIT Grant is being funded, then only 1/3 of the shares subject to this Option may be purchased.

Section 2.4 Notice of Corporate Action. If at any time:

(a) the Company shall take a record of the holders of its Common Stock or Series B stock for the purpose of entitling them to receive a dividend or other distribution, or any right to subscribe or purchase any evidences of indebtedness, any shares of stock of any class or any other securities or property, or to receive any other right, or

(b) there shall be any capital reorganization of the Company, any reclassification or recapitalization of the capital stock of the Company or any consolidation or merger of the Company with, or any sale, transfer or other disposition of all or substantially all of the property, assets or business of the Company to, another corporation or,

(c) there shall a voluntary or involuntary dissolution, liquidation or winding up of the Company; then, in any one or more of such cases, the Company shall give to Lender (i) at least 10 days’ prior written notice of the date on which a record date shall be selected for such dividend, distribution or right or for determining rights to vote in respect of any such reorganization, reclassification, merger, consolidation, sale, transfer, disposition, liquidation or winding up, and (ii) in the case of any such reorganization, reclassification, merger, consolidation, sale, transfer, disposition, dissolution, liquidation or winding up, at least 10 days’ prior written notice of the date when the same shall take place. Such notice in accordance with the foregoing clause also shall specify (x) the date on which any such record is to be taken for the purpose of such dividend, distribution or right, the date on which the holders of Common Stock or Series B Stock shall be entitled to any such dividend, distribution or right, and the amount and character thereof, and (y) the date on which any such reorganization, reclassification, merger, consolidation, sale, transfer, disposition, dissolution, liquidation or winding up is to take place and the time, if any such time is to be fixed, as of which the holders of Common Stock or Series B Stock shall be entitled to exchange their shares of Common Stock or series B Stock for securities or other property deliverable upon such disposition, dissolution, liquidation or winding up. Each such written notice shall be sufficiently given if addressed to Lender at the last address of Lender appearing on the books of the Company and delivered in accordance with Section 4.1.

Section 2.5 Restrictions on Securities. This Note has been issued by the Company pursuant to the exemption from registration under the Securities Act of 1933, as amended (the “Act”). None of this Note or the shares of Series B Stock issuable upon conversion of this Note may be offered, sold or otherwise transferred unless (i) they first shall have been registered under the Act and applicable state securities laws or (ii) the Company shall have been furnished with an opinion of legal counsel (in form, substance and scope reasonably acceptable to Company) to the effect that such sale or transfer is exempt from the registration requirements of the Act. Each certificate for shares of Series B Stock issuable upon conversion of this Note that have not been so registered and that have not been sold pursuant to an exemption that permits removal of the applicable legend, shall bear a legend substantially in the following form, as appropriate.

Upon the request of a holder of a certificate representing any shares of Series B Stock issuable upon conversion of this Note, the Company shall remove the foregoing legend from the certificate or issue to such Lender a new certificate free of any transfer legend, if (a) with such request, the Company shall have received an opinion of counsel, reasonably satisfactory to the Company in form, substance and scope, to the effect that any such legend may be removed from such certificate or (b) a registration statement under the Act covering such securities is in effect.

ARTICLE III

MISCELLANEOUS

Section 3.1 Notices. Any notice herein required or permitted to be given shall be in writing and may be personally served or delivered by courier or sent by United States mail and shall be deemed to have been given upon receipt if personally served (which shall include telephone line facsimile transmission) or sent by courier or three (3) days after being deposited in the United States mail, certified, with postage pre-paid and properly addressed, if sent by mail. For the purposes hereof, the address of the Lender shall be 341 Lakewood Drive, Bloomfield Hills, Michigan 48304; and the address of the Company shall be 57 West 57^th Street, Suite 400, New York, New York 10019. The Company shall accept electronic notice at “ ***@***”. Both the Lender and the Company may change the address for service by delivery of written notice to the other as herein provided.

Section 3.2 Entire Agreement and Amendment Provision. This Note represents the entire agreement between the parties hereto with respect to the subject matter hereof and there are no representations, warranties or commitments, except as set forth herein. This Note and any provision hereof may be amended only by an instrument in writing signed by the Company and the Lender.

Section 3.3 Assignability. This Note shall be binding upon the Company and its successors and assigns and shall inure to the benefit of the Lender and its successors and assigns; provided, however, that so long as no Event of Default has occurred, this Note shall only be transferable in whole subject to the restrictions contained in the restrictive legend on the first page of this Note.

Section 3.4 Governing Law. This Note shall be governed by the internal laws of the State of New York, without regard to conflicts of laws principles. The parties hereby submit to the exclusive jurisdiction and venue of the state or federal courts sited in the State of New Jersey with respect to any dispute arising under this Note.

Section 3.5 Replacement of Note. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Note, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which shall not include the posting of any bond), and upon surrender and cancellation of such Note, if mutilated, the Company will make and deliver a new Note of like tenor.

Section 3.6 This Note shall not entitle the Lender to any of the rights of a stockholder of the Company, including without limitation, the right to vote, to receive dividends and other distributions, or to receive any notice of, or to attend, meetings of stockholders or any other proceedings of the Company, unless and to the extent converted into shares of Series B Stock in accordance with the terms hereof.

Section 3.7 Severability. In case any provision of this Note is held by a court of competent jurisdiction to be excessive in scope or otherwise invalid or unenforceable, such provision shall be adjusted rather than voided, if possible, so that it is enforceable to the maximum extent possible, and the validity and enforceability of the remaining provisions of this Note will not in any way be affected or impaired thereby.

Section 3.8 Headings. The headings of the sections of this Note are inserted for convenience only and do not affect the meaning of such section.

Section 3.9 Counterparts. This Note may be executed in multiple counterparts, each of which shall be an original, but all of this shall be deemed to constitute one instrument.

IN WITNESS WHEREOF, with the intent to be legally bound hereby, the Company has executed this Note on November __ but effective as of October 28, 2019t.

EXHIBIT 1

CONVERSION NOTICE

TO:

The undersigned hereby irrevocably elects to convert US $__________ of the Principal Amount outstanding under the above Note into shares of Series B Convertible Stock of Cell Source, Inc., according to the conditions stated therein. If shares are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the Lender for any conversion, except for such transfer taxes, if any.

Conversion Date:_______________________________________________________

Applicable Conversion Price: $_____________________________________________

Signature:                           _________________________________________________

Name:                                 _________________________________________________

Address:                            _________________________________________________

                                            _________________________________________________

Tax I.D. or Soc. Sec. No.: _________________________________________________

Principal Amount to be converted: US $______________________________________

Amount of Note unconverted: US $_________________________________________

Number of shares of Series B Stock to be issued:_______________________________